AxoGen (NASDAQ:AXGN) Posts Earnings Results, Misses Expectations By $0.03 EPS

AxoGen (NASDAQ:AXGN) posted its earnings results on Tuesday. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03), Zacks reports. AxoGen had a negative net margin of 7.91% and a negative return on equity of 14.91%. AxoGen updated its FY 2025 guidance to EPS.

AxoGen Trading Up 0.1 %

Shares of NASDAQ:AXGN opened at $18.01 on Tuesday. The firm has a market capitalization of $792.62 million, a price-to-earnings ratio of -56.28 and a beta of 1.00. The business’s 50 day moving average price is $17.36 and its 200-day moving average price is $14.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen has a 1 year low of $5.55 and a 1 year high of $19.19.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lifted their price objective on shares of AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.